Valuation: Cell Source, Inc.

Market Cap 24.41M 21.81M 20.35M 18.48M 34.81M 2.36B 35.07M 245M 95.53M 1.2B 91.64M 89.66M 3.86B P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 34.92M 31.2M 29.11M 26.44M 49.8M 3.38B 50.17M 350M 137M 1.72B 131M 128M 5.52B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day+5.53%
1 week+21.66%
Current month+21.66%
1 month-3.54%
3 months-44.01%
6 months-31.75%
Current year-0.24%
1 week 0.36
Extreme 0.36
0.5
1 month 0.36
Extreme 0.36
0.58
Current year 0.25
Extreme 0.25
2.25
1 year 0.25
Extreme 0.25
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 2014-06-29
Director TitleAgeSince
Chairman 77 2015-05-17
Director/Board Member 82 2021-03-24
Director/Board Member 72 2022-03-09
Date Insider Type Main position Quantity % Market Cap. Importance
8/9/21 Others

Director

800,000 2.4492%
6/30/21 Others

Director

4,860 0.0149%
6/30/21 Others

Chairman

2,976 0.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+5.53%+21.66%+31.26%-23.26% 34.35M
+4.16%+4.16%+49.37%+94.17% 74.68B
-16.72%-17.09%+1.54%+49.42% 58.7B
-1.59%+1.32%+4.26%+32.40% 48.36B
+0.50%-2.14%+331.33%+702.20% 43.05B
-0.72%-3.99%+28.50%+29.94% 42.48B
+0.34%-0.52%+6.56%+109.35% 41.39B
-0.11%+1.96%+9.19%+52.66% 31.29B
-0.50%-3.10%-10.19%-14.35% 23.93B
-3.32%-10.86%-37.32%+316.28% 22.22B
Average -1.25%+0.20%+41.45%+134.88% 38.61B
Weighted average by Cap. -2.16%-1.56%+49.07%+144.67%

Financials

2023 2024
Net sales - -
Net income -5.32M -4.75M -4.44M -4.03M -7.59M -515M -7.64M -53.3M -20.83M -262M -19.98M -19.54M -842M -4.51M -4.03M -3.76M -3.42M -6.44M -437M -6.48M -45.2M -17.66M -222M -16.94M -16.57M -714M
Net Debt 9.27M 8.29M 7.73M 7.02M 13.23M 897M 13.32M 92.9M 36.29M 456M 34.82M 34.06M 1.47B 10.51M 9.39M 8.76M 7.96M 14.99M 1.02B 15.1M 105M 41.12M 517M 39.45M 38.6M 1.66B
Projected Income Statement - Annual - Cell Source, Inc.
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
-
Date Price Change Volume
26-10-07 US$0.4988 +5.53% 250
26-10-06 US$0.4727 +0.59% 3,600
26-10-05 US$0.4699 +17.47% 350
26-10-02 US$0.4000 -14.88% 4,575
26-10-01 US$0.4699 +14.61% 750
  1. Stock Market
  2. Stocks
  3. CLCS Stock